Summer 2025 Issue: Clinical Insights – MASH - Prime Therapeutics
Summer 2025 Issue: Clinical Insights – MASH
A new era in liver health: Treatment innovation, payer strategy, and pipeline momentum
Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic dysfunction–associated steatohepatitis (MASH)—a chronic liver disease affecting over 22 million U.S. adults.
This issue explores:
Treatment Innovation:
- FDA approval of Rezdiffra™, the first MASH-specific therapy
- GLP-1s like semaglutide showing promise in liver health
- Comparative insights and pipeline outlook
Payer Strategy:
- Cost projections and market growth through 2030
- Prime’s KeepWell™ solution for whole-person care
- Clinical guidance from AASLD, ADA, AGA, and EASL
Population Health:
- Risk factors and disparities in MASH prevalence
- Pediatric and lean MASLD considerations
- Diagnostic pathways and noninvasive tools
Explore how Prime is helping clients save, simplify, and support in the evolving MASH landscape.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.